10-K: Gyre Therapeutics FY25: Revenue Up, Cullgen Merger Planned

Gyre Therapeutics reports increased revenue in 2025 driven by new product launches and positive Phase 3 Hydronidone results, while announcing a merger with Cullgen Inc.

Summary

• Total revenue increased by 10.2% to $116.6 million in 2025 from $105.8 million in 2024.
• Net income decreased to $9.9 million in 2025 from $17.9 million in 2024, with net income attributable to common stockholders falling to $5.0 million from $12.1 million.
• ETUARY sales increased by $1.1 million to $106.1 million in 2025, representing 91.0% of total revenue.
• New products Etorel and Contiva, launched in 2025, generated $4.6 million and $5.5 million in sales, respectively.
• Hydronidone's pivotal Phase 3 trial in the PRC for CHB-associated liver fibrosis met its primary endpoint, with 52.85% of treated patients achieving 1-stage fibrosis regression at Week 52 (p=0.0002).
• The company announced an Agreement and Plan of Merger and Reorganization with Cullgen Inc. on March 2, 2026, an all-stock transaction valuing Cullgen at approximately $300 million.
• Cash and cash equivalents significantly increased to $37.1 million as of December 31, 2025, from $11.8 million in 2024.
• Accumulated deficit decreased to $68.4 million as of December 31, 2025, from $73.5 million in 2024.
• Operating expenses, including cost of revenues, selling and marketing, and research and development, all increased in 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and positive Phase 3 data for Hydronidone are strong positives, the significant decline in net income, increased operating expenses, and ongoing regulatory and competitive challenges, coupled with the uncertainty of the Cullgen merger, temper overall sentiment.

Positives

• Total revenue increased by 10.2% to $116.6 million in 2025, driven by new product launches.
• ETUARY sales increased by $1.1 million to $106.1 million in 2025, maintaining a leading market position in IPF in the PRC.
• Successful commercial launch of Etorel, generating $4.6 million in sales in 2025, and Contiva, generating $5.5 million in sales in 2025.
• Hydronidone's pivotal Phase 3 trial in the PRC for CHB-associated liver fibrosis met its primary endpoint, with 52.85% of treated patients achieving 1-stage fibrosis regression at Week 52 (p=0.0002).
• Hydronidone was well tolerated in the Phase 3 trial, with comparable serious adverse events (4.88% vs. 6.45% placebo) and no discontinuations due to adverse events.
• The CDE indicated that existing Phase 3 data for Hydronidone supports submission for conditional approval and potential priority review eligibility in the PRC.
• The NMPA approved the trial application for ETUARY in Radiation-Induced Lung Injury (RILI) in March 2025.
• The IND for F230 for Pulmonary Arterial Hypertension (PAH) was approved by the NMPA in May 2024, with Phase 1 initiated in June 2025.
• Cash and cash equivalents significantly increased to $37.1 million as of December 31, 2025, from $11.8 million in 2024.
• Accumulated deficit decreased to $68.4 million as of December 31, 2025, from $73.5 million in 2024.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Net income decreased significantly from $17.9 million in 2024 to $9.9 million in 2025.
• Net income attributable to common stockholders decreased from $12.1 million in 2024 to $5.0 million in 2025.
• ETUARY's market share has declined in recent periods due to increased competition from other approved IPF therapies.
• Sales of Etorel and Contiva were lower than internal budget expectations due to early-year supply chain and distribution delays and cautious purchasing behavior related to volume-based procurement.
• The market size for Acute Liver Failure (ALF) and Acute-on-Chronic Liver Failure (ACLF) in the PRC is projected to decline from $240.6 million in 2024 to $191.1 million in 2032.
• The Pulmonary Arterial Hypertension (PAH) market in the PRC is projected to grow slowly, from $400 million in 2024 to $480 million by 2032 (2.28% CAGR).
• Cost of revenues increased by 39.4% to $5.4 million in 2025.
• Selling and marketing expenses increased by 13.3% to $65.2 million in 2025.
• General and administrative expenses increased by 29.1% to $20.8 million in 2025.
• The change in fair value of warrant liability decreased by $4.5 million, impacting income.
• The merger with Cullgen Inc. involves substantial expenses and potential dilution for current stockholders.
• WuXi Biologics, a manufacturer for Hydronidone API, is identified in the U.S. BIOSECURE Act, posing potential supply chain risks and restrictions on U.S. federal government business or grants.

Risks

• There is no assurance when or if the Merger with Cullgen will be completed, and any delay may substantially reduce the potential benefits.
• The business is significantly dependent on the sales of ETUARY in the PRC amid a competitive landscape, and there is a possibility that sales volume, pricing, and profitability may not be sustained or boosted.
• Marketed products (ETUARY, Etorel, Contiva) and any future approved products may not attain sufficient market acceptance among physicians, healthcare facilities, pharmacies, patients, and third-party payers.
• The future of the business and financial outcomes is largely contingent on the progress and success of product candidates (ETUARY for future indications, F573, Hydronidone); risk of not finalizing clinical development, securing necessary regulatory approvals, or accomplishing market launch successfully.
• Further funding is required for R&D activities and operations, which might not be obtainable on favorable terms or could be entirely unavailable, potentially leading to delays or halts in development projects.
• The company may fail to win bids to sell commercialized products to PRC public hospitals through the centralized tender process.
• The true market potential for products and product candidates may be less than expected, constrained by the current and emerging number of IPF patients in the PRC, pending approval and profitable launch of expanded applications for ETUARY, and other product candidates.
• The approval procedures of the NMPA, FDA, and comparable foreign regulatory authorities are extensive, protracted, and inherently uncertain, potentially delaying or preventing marketing of product candidates.
• Failure to secure, uphold, defend, or extend adequate patent and other intellectual property rights for products and product candidates globally could compromise the ability to effectively compete.
• Collaborative agreements and strategic partnerships may not achieve anticipated benefits, and conflicts could emerge with present or prospective partners.
• Clinical drug development involves a lengthy and expensive process with uncertain outcomes; may not successfully complete clinical trials or demonstrate safety and efficacy to regulatory authorities.
• Ongoing success is reliant on the capacity to retain key executives and to recruit, maintain, and inspire skilled professionals.
• If intangible assets are impaired, results of operations and financial condition may be adversely affected.
• There are uncertainties regarding the interpretation and enforcement of PRC laws, rules, and regulations.
• The market price of common stock has been, and may continue to be, volatile.
• The company will continue to incur significant costs as a public company, and management is required to devote substantial time to compliance.
• The issuance, or expected issuance, of common stock in connection with the Merger could decrease the market price of common stock.
• The intended benefits of the Merger may not be realized, posing risks for ongoing operations.
• During the pendency of the Merger, the company may not be able to enter into a business combination with another party and will be subject to contractual limitations on certain actions.
• The Exchange Ratio for the Merger is not adjustable based on the market price of common stock, so the merger consideration value may fluctuate.
• Substantial expenses related to the Merger with Cullgen are expected.
• Failure to complete the Merger could negatively affect the value of common stock and future business and financial results.
• The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes, or other causes.
• The company and/or its board of directors may become involved in securities litigation or stockholder derivative litigation in connection with the Merger.
• The company is substantially dependent on its remaining employees, key contractors, and consultants to facilitate the consummation of the Merger.
• The high gross margin during 2025 and 2024 may not be sustainable.
• The five largest customers accounted for a substantial amount of revenue, subjecting the company to concentration risks.
• Risk regarding the obsolescence of inventories.
• Credit risk in collecting trade receivables due from customers.
• The company has historically received government grants and preferential tax treatment, but may not continue to receive such financial incentives in the future.
• Products may cause or be perceived to cause significant adverse events, toxicities, or other undesirable side effects that may interrupt, delay, or halt clinical trials or prevent regulatory approval.
• Breakthrough Therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood of marketing approval.
• Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and problems may be encountered during the process.
• The use of foreign CROs and contract manufacturing organizations (CMOs), including WuXi Biologics (identified in the BIOSECURE Act), could increase costs, reduce supply, delay procurement, or restrict the ability to work with such CMOs.
• Business disruptions due to natural or man-made disasters, health epidemics, or other events could seriously harm future revenue and financial condition.
• Limited insurance coverage, and any claims beyond insurance coverage may result in substantial costs and a diversion of resources.
• Adverse drug reactions and negative results from off-label use of commercialized products could materially harm business reputation, product brand name, and financial condition.
• The company may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on more profitable opportunities.
• The company may be unable to identify, discover, or develop new product candidates or additional therapeutic opportunities to expand or maintain its product pipeline.
• Results from preclinical or early stage clinical trials may not be confirmed in later trials or be predictive of success.
• Delays or difficulties in the commencement of clinical trials or patient enrollment could delay or prevent regulatory approvals.
• Commercialized products may be excluded or removed from national, provincial, or other government-sponsored medical insurance programs.
• The company may face pressure to lower the prices of commercialized products to qualify for medical insurance reimbursement or due to market competition.
• Future policies of centralized volume-based procurement set by the PRC government may cover commercialized products, leading to price decreases.
• The true market potential for products and product candidates may be less than expected, constrained by the number of patients.
• The company may be unable to conduct effective academic marketing or maintain a qualified sales and marketing force.
• Failure to maintain or expand an effective distribution network for commercialized products.
• Failure to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry.
• Geopolitical events and global economic conditions may impact third-party supply of raw materials and components.
• The company and its contract manufacturers are subject to significant regulation with respect to manufacturing; delays in approvals for facilities could delay development plans.
• Substantial disruption to production sites and problems in manufacturing products.
• The company may not be able to meet increasing demand for commercialized products, maintain adequate manufacturing capacity, or successfully manage anticipated growth.
• Fluctuations in prices of raw materials and energy supply, as well as other production costs, may have a material adverse effect if not passed on to customers.
• Failure to maintain optimal inventory levels could increase operating costs or lead to unfulfilled customer orders.
• Changes in patent law could diminish the value of patents generally, impairing the ability to protect intellectual property.
• The company may need to license certain intellectual property from third parties, and such licenses may not be available or on commercially reasonable terms.
• Failure to protect trademarks and trade names may negatively affect the ability to build brand recognition.
• Intellectual property rights may not address all potential threats to the business or competitive advantage.
• Relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Exposure to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-corruption and anti-bribery laws, as well as export controls, trade sanctions, and import laws.
• Results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.
• The company is subject to evolving privacy and data protection laws (HIPAA, GDPR, PRC laws); failure to comply could materially adversely affect business.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Extensive ongoing regulatory obligations and continued regulatory review related to commercialized products.
• The PRC government may exert influence over Gyre Pharmaceuticals' operations, which could result in an adverse change.
• The pharmaceutical industry in the PRC is highly regulated and regulations are subject to change, affecting approval and commercialization.
• Changes in political, economic, and other policies of the PRC government could have a material adverse effect on overall economic growth.
• Restrictions on currency exchange may limit Gyre Pharmaceuticals' ability to receive and use foreign currency financing or Gyre Therapeutics' ability to transfer cash from Gyre Pharmaceuticals.
• PRC regulations relating to the establishment of offshore special purpose companies by residents in the PRC may subject PRC resident beneficial owners to liability or penalties.
• Failure to comply with PRC regulations regarding the registration requirements for employee equity incentive plans may subject the company to fines and sanctions.
• Gyre Pharmaceuticals' classification as a PRC tax resident results in unfavorable tax consequences.
• Uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company.
• The enacted Holding Foreign Companies Accountable Act (HFCAA) and Accelerating Holding Foreign Companies Accountable Act could add uncertainties to the market for common stock.
• Many product candidates are years away from regulatory approval.
• Fluctuations in operating results could adversely affect the price of common stock.
• Sales of a significant number of shares of common stock in the public markets, or the perception that such sales could occur, could depress the market price.
• Provisions in the certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the Company more difficult.
• The exclusive forum provision in the certificate of incorporation and bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• The company does not anticipate paying any cash dividends in the foreseeable future.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its stock price and trading volume could decline.
• The ability to utilize net operating loss carryforwards and tax credit carryforwards may be subject to limitations.
• Changes in tax laws or their implementation may adversely affect the business and financial condition.
• The company is a controlled company within the meaning of Nasdaq listing standards and relies on exemptions from certain corporate governance requirements.
• Executive officers, directors, and principal stockholders have the ability to control or significantly influence all matters submitted to stockholders for approval.
• The company may be exposed to increased litigation, including stockholder litigation.
• Breach, failure, or disruption in or to the information system could compromise sensitive information and expose the company to liability or reputational harm.
• Investors may have difficulty enforcing judgments obtained against the company due to assets located outside of the United States.
• Failure to maintain proper and effective internal controls over financial reporting could impair the ability to produce accurate and timely financial statements.

Future Outlook

The company expects to submit an NDA for conditional approval of Hydronidone in CHB-associated liver fibrosis in the PRC in the first half of 2026. It also plans to file a U.S. IND for Hydronidone in MASH-associated liver fibrosis in 2026 and, if effective, initiate a Phase 2 clinical trial. An adaptive Phase 2/3 study for ETUARY in RILI is expected to initiate in the first half of 2026, and an IND for F528 in COPD is anticipated in the first quarter of 2027. The merger with Cullgen Inc. is expected to close, subject to stockholder approval and HSR Act filing.

Management Comments

• Our strategy is to leverage our established commercial portfolio to support and de-risk the advancement of late-stage product candidates, expand approved products into additional indications, and build a diversified pipeline targeting significant unmet medical needs in fibrosis and related inflammatory diseases.
• We believe that our existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund our operating activities and obligations for at least 12 months following the issuance of these consolidated financial statements.
• We are actively monitoring potential implications for our manufacturing and supply chain arrangements [related to the BIOSECURE Act]... and are evaluating contingency plans, including identifying alternative contract development and manufacturing organizations that could support future U.S. clinical supply, if necessary.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in fibrosis and inflammatory diseases, is highly competitive and characterized by rapid innovation. The company's strategy of leveraging existing commercial products in the PRC to fund innovative pipeline development in both the PRC and U.S. is a common approach to de-risk R&D. The MASH market is seeing increasing investment and competition, with several drug classes and specific candidates (e.g., Resmetirom, VK2809, Pegozafermin) in advanced development, highlighting the need for Gyre's Hydronidone to demonstrate strong differentiation. The declining prevalence and market size for ALF/ACLF in the PRC, despite unmet need, suggests a challenging commercial environment for F573. The slow growth in the PAH market also indicates a niche but competitive space for F230. The mention of the BIOSECURE Act and tariffs reflects broader geopolitical and trade tensions impacting global pharmaceutical supply chains, particularly those involving China.

Comparison to Industry Standards

• Hydronidone's Phase 3 results for CHB-associated liver fibrosis (52.85% fibrosis regression vs. 29.84% placebo) are significant, especially as no small molecule or biologic drugs treating CHB-associated liver fibrosis have been approved globally. This positions Hydronidone as a potential first-in-class therapy.
• In the MASH market, Resmetirom (Madrigal Pharmaceuticals, Inc.) was the first FDA-approved drug for noncirrhotic MASH with moderate to advanced liver fibrosis. Other competitors like Viking Therapeutics (VK2809), NGM Biopharmaceuticals (Aldafermin), Akero Therapeutics (Efruxifermin), 89bio (Pegozafermin, acquired by Roche), Galectin Therapeutics (Belapectin), Galmed Pharmaceuticals (Aramchol), Novo Nordisk (Semaglutide), Altimmune (Pemvidutide/ALT-801), Eli Lilly (Tirzepatide), Inventiva (Lanifibranor), Boston Pharmaceuticals (BOS-580), and Genentech (BFKB8488A) are developing therapies, indicating a crowded and competitive landscape for Hydronidone in the U.S.
• ETUARY (pirfenidone) and Etorel (nintedanib) are standard-of-care antifibrotic therapies for IPF, aligning with international treatment guidelines.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal proceedings.
• From time to time, the company may become involved in legal proceedings arising in the ordinary course of business, which could have an adverse impact due to defense and settlement costs, diversion of management resources, and reputational harm.

Related Party Transactions

• No research and development fees were paid to GNI Group during the year ended December 31, 2025, compared to $0.2 million in 2024.
• As of December 31, 2025 and 2024, the company had $0.2 million in other receivables from GNI Group related to Continent Pharmaceuticals Inc.'s (CPI) restructuring transaction.
• In October 2023, the company issued 811 shares of Convertible Preferred Stock and 811 Preferred Stock Warrants to GNI USA, Inc. (indirectly wholly owned by GNI Group Ltd.) in a private placement.
• In November 2023, GNI USA converted its 13,151 shares of Convertible Preferred Stock into common stock.
• In September 2020, Gyre Pharmaceuticals entered into an IP transfer agreement with GNI Japan and certain of its wholly owned subsidiaries (the GNI Group) for Hydronidone IP rights, which includes milestone and royalty payment obligations.
• The GNI Parties control a majority of the voting power of the company's outstanding common stock, resulting in the company qualifying as a 'controlled company' under Nasdaq listing standards.

Stakeholder Impact

• Shareholders face potential dilution from the Cullgen merger and future capital raises, as well as stock price volatility due to market conditions, clinical trial results, and competitive landscape. They also have reduced protections due to the company's 'controlled company' status and no anticipated cash dividends.
• Employees may experience uncertainty about future roles due to the Cullgen merger. The company's success depends on retaining key executives and recruiting skilled professionals in a competitive market, with stock options forming part of compensation.
• Customers (distributors, hospitals, pharmacies) are impacted by product pricing, market acceptance, and inclusion in national reimbursement lists and centralized procurement programs in the PRC.
• Patients may gain access to new therapies for organ fibrosis and inflammatory diseases (IPF, MASH, CHB, PD, RILI, ALF/ACLF, PAH, COPD), with the safety and efficacy profiles of new drugs being critical.
• Suppliers and manufacturers face potential risks from geopolitical events, trade tensions (e.g., BIOSECURE Act, tariffs), and supply chain disruptions, particularly for raw materials and contract manufacturing organizations.
• Creditors are impacted by the company's financial health, ability to generate revenue, and manage debt obligations.

Next Steps

• Submit NDA seeking conditional approval for Hydronidone in CHB-associated liver fibrosis in the PRC in the first half of 2026.
• Initiate an adaptive Phase 2/3 study for ETUARY in RILI in the first half of 2026.
• File a U.S. IND for Hydronidone in MASH-associated liver fibrosis in 2026 and, if effective, initiate a Phase 2 clinical trial.
• Complete F573 Phase 2 clinical trial in 2026.
• Conduct a hepatic impairment study in U.S. subjects for Hydronidone.
• Conduct an additional confirmatory clinical trial for Hydronidone in CHB-associated liver fibrosis to support conversion from conditional to regular approval.
• Anticipate submitting an IND application to the NMPA for F528 in the first quarter of 2027.
• Enter into procurement contracts with various participating hospitals under the National Centralized Drug Procurement program for Etorel.
• Complete the merger with Cullgen Inc., subject to stockholder approval and HSR Act filing.
• Convene a meeting of stockholders to approve the conversion of Company Preferred Stock into Company Common Stock related to the Cullgen merger.

Key Dates

Recommendation

The company presents a mixed financial picture with revenue growth driven by new product launches and positive Phase 3 data for Hydronidone, indicating strong pipeline potential. However, the significant decline in net income and increased operating expenses, coupled with intense competition and regulatory uncertainties in key markets (PRC and U.S.), suggest caution. The pending merger with Cullgen introduces both opportunities and risks, including potential dilution and integration challenges. A 'hold' recommendation is appropriate as investors await further clarity on the merger's successful integration, the commercialization trajectory of new products, and the progression of pipeline candidates through regulatory approvals, particularly Hydronidone in the U.S. MASH market.

Keywords

Biopharmaceutical, Organ Fibrosis, Inflammatory Diseases, ETUARY, Pirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Hydronidone, MASH, CHB-associated liver fibrosis, Etorel, Nintedanib, Contiva, Avatrombopag, Thrombocytopenia, ALF/ACLF, F573, PAH, F230, COPD, F528, Clinical Trials, Drug Development, SEC Filing, 10-K, China, United States, Cullgen Merger, Regulatory Approval, Intellectual Property